Today's Pharmaceutical Executive Daily covers key news in the pharmaceutical and life sciences industry.
The FDA has approved Bayer's Lynkuet (elinzanetant) for treating moderate to severe vasomotor symptoms associated with menopause.
New research suggests Ozempic may reduce biological age.
Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.
No direct quote available in the given text.
Author's summary: New research on Ozempic and FDA approval of Lynkuet.